Combined weekly carboplatin and paclitaxel as primary treatment of advanced epithelial ovarian carcinoma

Gynecologic Oncology

Volumn 114, Issue 2, 2009, Pages 215-218

  Safra, Tamar ^a   Menczer, Joseph ^b   Bernstein, Rinat Molho ^a   Shpigel, Shulem ^a   Matcejevsky, Dianna ^a   Inbar, Moshe J ^a   Golan, Abraham ^b   Grisaru, Dan ^a   Levy, Tally ^b  

^a TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^b WOLFSON MEDICAL CENTER   (Israel)

Author keywords

Ovarian cancer; Toxicity; Weekly combined carboplatin and paclitaxel

Indexed keywords

CARBOPLATIN; CIMETIDINE; DEXAMETHASONE; DIPHENHYDRAMINE; DOCETAXEL; GRANULOCYTE COLONY STIMULATING FACTOR; PACLITAXEL; RANITIDINE; RECOMBINANT ERYTHROPOIETIN;

ADJUVANT THERAPY; ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; CYTOREDUCTIVE SURGERY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHY; NEUTROPENIA; OUTCOME ASSESSMENT; OVARY CARCINOMA; PHASE 2 CLINICAL TRIAL; POSTOPERATIVE CARE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; EPITHELIAL CELLS; FEMALE; HUMANS; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; OVARIAN NEOPLASMS; PACLITAXEL; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 67549150461     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2009.04.008     Document Type: Article

References (23)

1. Jemal A., Siegel R., Ward E., Murray T., Xu J., Smigal C., et al. Cancer statistics, 2006. CA. Cancer J. Clin. 56 (2006) 106-130
2. Ozols R.F., Bundy B.N., Greer B.E., Fowler J.M., Clarke-Pearson D., Burger R.A., et al., Gynecologic Oncology Group. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J. Clin. Oncol. 21 (2003) 3194-3200
3. du Bois A., Luck H.J., Meier W., Adams H.P., Mobus V., Costa S., et al., Arbeitsgemeinschaft Gynakologische Onkologie Ovarian Cancer Study Group. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J. Natl. Cancer Inst. 95 (2003) 1320-1329
4. Lorusso D., Ferrandina G., Greggi S., Gadducci A., Pignata S., Tateo S., et al., Multicenter Italian Trials in Ovarian Cancer Investigators. Phase III multicenter randomized trial of amifostine as cytoprotectant in first-line chemotherapy in ovarian cancer patients. Ann. Oncol. 14 (2003) 1086-1093
5. Vasey P.A., Jayson G.C., Gordon A., Gabra H., Coleman R., Atkinson R., et al., Scottish Gynaecological Cancer Trials Group. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J. Natl. Cancer Inst. 96 (2004) 1682-1691
6. Skarlos D.V., Aravantinos G., Kosmidis P., Athanassiadis A., Stathopoulos G.P., Pavlidis N., et al. Paclitaxel with carboplatin versus paclitaxel with carboplatin alternating with cisplatin as first-line chemotherapy in advanced epithelial ovarian cancer: preliminary results of a Hellenic Cooperative Oncology Group study. Semin. Oncol. 24 Suppl 15 (1997) S15-57-S15-61
7. Neijt J.P., Engelholm S.A., Tuxen M.K., Sorensen P.G., Hansen M., Sessa C., et al. Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer. J. Clin. Oncol. 18 (2000) 3084-3092
8. Ozols R.F., Bundy B.N., Greer B.E., Fowler J.M., Clarke-Pearson D., Burger R.A., et al., Gynecologic Oncology Group. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J. Clin. Oncol. 21 (2003) 3194-3200
9. Pignata S., De Placido S., Biamonte R., Scambia G., Di Vagno G., Colucci G., et al. Residual neurotoxicity in ovarian cancer patients in clinical remission after first-line chemotherapy with carboplatin and paclitaxel: the Multicenter Italian Trial in Ovarian cancer (MITO-4) retrospective study. BMC Cancer 6 (2006) 5
10. Gianni L., Kearns C.M., Giani A., Capri G., Vigano L., Lacatelli A., et al. Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans. J. Clin. Oncol. 13 (1995) 180-190
11. Pasquier E., Honore S., Pourroy B., Jordan M.A., Lehmann M., Briand C., et al. Antiangiogenic concentrations of paclitaxel induce an increase in microtubule dynamics in endothelial cells but not in cancer cells. Cancer Res. 65 (2005) 2433-2440
12. Jordan M.A., Wendell K., Gardiner S., Derry W.B., Copp H., and Wilson L. Mitotic block induced in HeLa cells by low concentrations of paclitaxel (Taxol) results in abnormal mitotic exit and apoptotic cell death. Cancer Res. 56 (1996) 816-825
13. Jordan M.A., Toso R.J., Thrower D., and Wilson L. Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations. Proc. Natl. Acad. Sci. U. S. A. 90 (1993) 9552-9556
14. Abu-Rustum N.R., Aghajanian C., Barakat R.R., Fennelly D., Shapiro F., and Spriggs D. Salvage weekly paclitaxel in recurrent ovarian cancer. Semin. Oncol. 24 (1997) S15-S67
15. Fennelly D., Aghajanian F., Shapiro F., O'Flaherty C., McKenzie M., O'Connor C., et al. Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer. J. Clin. Oncol. 15 (1997) 187-192
16. Yamashita Y., Kataoka K., Ishida T., Matsuura M., Seno N., Mukaida H., et al. A feasibility study of postoperative adjuvant therapy of carboplatin and weekly paclitaxel for completely resected non-small cell lung cancer. J. Thorac. Oncol. 3 (2008) 612-616
17. Belani C.P., Ramalingam S., Perry M.C., LaRocca R.V., Rinaldi D., Gable P.S., et al. Randomized, phase III study of weekly paclitaxel in combination with carboplatin versus standard every-3-weeks administration of carboplatin and paclitaxel for patients with previously untreated advanced non-small-cell lung cancer. J. Clin. Oncol. 26 (2008) 468-473
18. Ramalingam S., Barstis J., Perry M.C., La Rocca R.V., Nattam S.R., Rinaldi D., et al., China Gynecological Oncology Group (CGOG). [A multicenter randomized clinical trial of weekly paclitaxel and carboplatin vs three weeks paclitaxel and carboplatin as first line chemotherapy in epithelial ovarian cancer]. Zhonghua Yi Xue Za Zhi 85 (2005) 2099-2103
19. Sehouli J., Stengel D., Mustea A., Camara O., Keil E., Elling D., et al., Ovarian Cancer Study Group of the Nord-Ostdeutsche Gesellschaft für Gynäkologische Onkologie. Weekly paclitaxel and carboplatin (PC-W) for patients with primary advanced ovarian cancer: results of a multicenter phase-II study of the NOGGO. Cancer Chemother. Pharmacol. 61 (2008) 243-250
20. Seidman A.D., Hudis C.A., Albanel J., Tong W., Tepler I., Currie V., et al. Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer. J. Clin. Oncol. 16 (1998) 3353-3361
21. Norton L. Evolving concepts in the systemic drug therapy of breast cancer. Semin. Oncol. 24 Suppl 10 (1997) S10.3-S10.10
22. Leiser A.L., Maluf F.C., Chi D.S., Sabbatini P., Hensley M.L., Schwartz L., et al. A phase I study evaluating the safety and pharmacokinetics of weekly paclitaxel and carboplatin in relapsed ovarian cancer. Int. J. Gynecol. Cancer 17 (2007) 379-386
23. Isonishi S, Yasuda M, Takahashi F, Katsumata N, Kimura E, Aoki D, et al. Randomized phase III trial of conventional paclitaxel and carboplatin (c-TC) versus dose dense weekly paclitaxel and carboplatin (dd-TC) in women with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer: Japanese Gynecologic Oncology. J Clin Oncol 2008;26:(suppl; abstr 5506).